ASX:CP1

CannPal Animal Therapeutics (CP1) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CP1 stock logo

About CannPal Animal Therapeutics Stock (ASX:CP1)

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.

CP1 Stock News Headlines

How do animals grow?
Experimenting on animals
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Weird Animals
The animals that could be dreaming
How animals reproduce
Elanco Animal Health (NYSE: ELAN)
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Animal attacks
The ethics of speciesism
Talking Animals
Animals
Animal Abuse
'Forever chemicals' found in animals around the world
See More Headlines
Receive CP1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CannPal Animal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$802,623.00
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Layton Patrick Mills
    Founder, MD & Director
  • Dr. Margaret Curtis
    Head of Clinical Devel. and R&D
  • Mr. Baden Maxwell Bowen
    CFO & Company Sec.
  • Dr. Rayson Tan
    Chief Scientific Officer & Member of Advisory Board

This page (ASX:CP1) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners